Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective

The opioids are commonly used to treat acute and severe pain. Long-term opioid administration eventually reaches a dose ceiling that is attributable to the rapid onset of analgesic tolerance coupled with the slow development of tolerance to the untoward side effects of respiratory depression, nausea and decreased gastrointestinal motility. The need for effective-long term analgesia remains. In order to develop new therapeutics and novel strategies for use of current analgesics, the processes that mediate tolerance must be understood. This review highlights potential pharmacokinetic (changes in metabolite production, metabolizing enzyme expression, and transporter function) and pharmacodynamic (receptor type, location and functionality; alterations in signaling pathways and cross-tolerance) aspects of opioid tolerance development, and presents several pharmacodynamic modeling strategies that have been used to characterize time-dependent attenuation of opioid analgesia.

[1]  S. Schulz,et al.  Effect of the A118G polymorphism on binding affinity, potency and agonist‐mediated endocytosis, desensitization, and resensitization of the human mu‐opioid receptor , 2004, Journal of neurochemistry.

[2]  Karen E. Redwine,et al.  Effects of NMDA receptor antagonists on acute μ-opioid analgesia in the rat , 2003, Pharmacology Biochemistry and Behavior.

[3]  M. Narita,et al.  Heterologous µ‐opioid receptor adaptation by repeated stimulation of κ‐opioid receptor: up‐regulation of G‐protein activation and antinociception , 2003, Journal of neurochemistry.

[4]  J. Svensson,et al.  Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence. , 1983, British journal of clinical pharmacology.

[5]  M. Millan.  Kappa-opioid receptor-mediated antinociception in the rat. I. Comparative actions of mu- and kappa-opioids against noxious thermal, pressure and electrical stimuli. , 1989, The Journal of pharmacology and experimental therapeutics.

[6]  G. Aghajanian,et al.  Molecular and cellular basis of addiction. , 1997, Science.

[7]  E. Heinzen,et al.  Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development , 2004, Brain Research.

[8]  G. Uhl,et al.  -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. , 1994, The Journal of biological chemistry.

[9]  H. Shannon,et al.  Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats , 2002, Neuropharmacology.

[10]  C. L. Graff,et al.  Variable modulation of opioid brain uptake by P-glycoprotein in mice. , 2004, Biochemical pharmacology.

[11]  A. Coop,et al.  Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. , 2007, Journal of pharmaceutical sciences.

[12]  E. Heinzen,et al.  The development of morphine antinociceptive tolerance in nitric oxide synthase-deficient mice. , 2004, Biochemical pharmacology.

[13]  M. Suarez‐Almazor,et al.  Opioid rotation for toxicity reduction in terminal cancer patients. , 1995, Journal of pain and symptom management.

[14]  B. Yoburn,et al.  μ-Opioid receptor downregulation contributes to opioid tolerance in vivo , 2001, Pharmacology Biochemistry and Behavior.

[15]  A. Duttaroy,et al.  The Effect of Intrinsic Efficacy on Opioid Tolerance , 1995, Anesthesiology.

[16]  C. Inturrisi.  Clinical Pharmacology of Opioids for Pain , 2002, The Clinical journal of pain.

[17]  R. Gainetdinov,et al.  Enhanced morphine analgesia in mice lacking beta-arrestin 2. , 1999, Science.

[18]  M. Karlsson,et al.  Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling. , 1998, Journal of pharmaceutical sciences.

[19]  B. Berkowitz.  The Relationship of Pharmacokinetics to Pharmacological Activity: Morphine, Methadone and Naloxone , 1976, Clinical pharmacokinetics.

[20]  S. Sharma,et al.  Evidence for a role of N-Methyl-d-aspartate receptors in l-arginine-induced attenuation of morphine antinociception , 1998, Brain Research.

[21]  M. Kreek,et al.  Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments , 2005, Pharmacological Reviews.

[22]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  F. F. Weight,et al.  Differential Opiate Receptor Phosphorylation and Desensitization Induced by Agonists and Phorbol Esters (*) , 1996, The Journal of Biological Chemistry.

[24]  G. Pollack,et al.  Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. , 1997, Biochemical pharmacology.

[25]  Y. Kolesnikov,et al.  Evaluation of the tail formalin test in mice as a new model to assess local analgesic effects , 2004, Brain Research.

[26]  Lakshmi A. Devi,et al.  Targeting opioid receptor heterodimers: Strategies for screening and drug development , 2006, The AAPS Journal.

[27]  G. Pasternak,et al.  Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs , 2001, Nature Neuroscience.

[28]  R. Dallel,et al.  Synergistic Antinociceptive Effect of Amitriptyline and Morphine in the Rat Orofacial Formalin Test , 2004, Anesthesiology.

[29]  S. Bartlett,et al.  The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. , 1994, Life sciences.

[30]  J. Whistler,et al.  Endocytosis of the Mu Opioid Receptor Reduces Tolerance and a Cellular Hallmark of Opiate Withdrawal , 2001, Neuron.

[31]  M. Gibaldi,et al.  Dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetic characteristics. , 1972, Journal of pharmaceutical sciences.

[32]  D. Pfaff,et al.  Frequent colocalization of mu opioid and NMDA‐type glutamate receptors at postsynaptic sites in periaqueductal gray neurons , 1999, The Journal of comparative neurology.

[33]  S. Siegel.  Morphine analgesic tolerance: its situation specificity supports a Pavlovian conditioning model. , 1976, Science.

[34]  M. Caron,et al.  Prolonged Kappa Opioid Receptor Phosphorylation Mediated by G-protein Receptor Kinase Underlies Sustained Analgesic Tolerance* , 2004, Journal of Biological Chemistry.

[35]  G. Uhl,et al.  μ Opioid Receptor Phosphorylation, Desensitization, and Ligand Efficacy* , 1997, The Journal of Biological Chemistry.

[36]  L. Dykstra,et al.  Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude. , 2000, The Journal of pharmacology and experimental therapeutics.

[37]  S. Snyder,et al.  Opiate receptors and beyond: 30 years of neural signaling research , 2004, Neuropharmacology.

[38]  G. Lauretti,et al.  Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. , 1999, Anesthesiology.

[39]  E. Heinzen,et al.  Use of an electrochemical nitric oxide sensor to detect neuronal nitric oxide production in conscious, unrestrained rats. , 2002, Journal of pharmacological and toxicological methods.

[40]  G. M. Pollack,et al.  A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[41]  G. M. Pollack,et al.  In Vivo Activation of Human Pregnane X Receptor Tightens the Blood-Brain Barrier to Methadone through P-Glycoprotein Up-Regulation , 2006, Molecular Pharmacology.

[42]  K. Neville,et al.  Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. , 2006, The oncologist.

[43]  J. Lötsch,et al.  The μ-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers , 2006 .

[44]  J. Leander,et al.  The behavioral pharmacology of NMDA receptor antagonists. , 1990, Trends in pharmacological sciences.

[45]  D. Hurlbut,et al.  Blockade of morphine-induced analgesia and tolerance in mice by MK-801 , 1993, Brain Research.

[46]  V. Pickel,et al.  Dual Ultrastructural Localization of μ-Opioid Receptors and NMDA-Type Glutamate Receptors in the Shell of the Rat Nucleus Accumbens , 1997, The Journal of Neuroscience.

[47]  S. Kaasa,et al.  Long term methadone for chronic pain: A pilot study of pharmacokinetic aspects , 2007, European journal of pain.

[48]  K. Hirota,et al.  The effects of recombinant rat μ‐opioid receptor activation in CHO cells on phospholipase C, [Ca2+]i and adenylyl cyclase , 1997, British journal of pharmacology.

[49]  Maree T. Smith,et al.  Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat , 1995, Pain.

[50]  E. Heinzen,et al.  Pharmacokinetics and pharmacodynamics of l-arginine in rats: a model of stimulated neuronal nitric oxide synthesis , 2003, Brain Research.

[51]  H. Bhargava,et al.  Mechanism of attenuation of morphine antinociception by chronic treatment with L-arginine. , 1997, The Journal of pharmacology and experimental therapeutics.

[52]  C. Parsons,et al.  Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain , 2004, Neuropharmacology.

[53]  J. Kemp,et al.  NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.

[54]  B. Kieffer.  Opioids: first lessons from knockout mice. , 1999, Trends in pharmacological sciences.

[55]  Lakshmi A. Devi,et al.  G-protein-coupled receptor heterodimerization modulates receptor function , 1999, Nature.

[56]  R. Coggeshall,et al.  Inflammation-induced changes in peripheral glutamate receptor populations , 1999, Brain Research.

[57]  A. Dahan,et al.  Polymorphism of &mgr;-Opioid Receptor Gene (OPRM1:c.118A>G) Does Not Protect Against Opioid-induced Respiratory Depression despite Reduced Analgesic Response , 2005, Anesthesiology.

[58]  A. Lipkowski,et al.  Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. , 1989, The Journal of pharmacology and experimental therapeutics.

[59]  S. Allouche,et al.  Different Regulation of Human δ-Opioid Receptors by SNC-80 [(+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and Endogenous Enkephalins , 2004, Journal of Pharmacology and Experimental Therapeutics.

[60]  Marc G. Caron,et al.  μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence , 2000, Nature.

[61]  D. Taylor,et al.  Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. , 2001, The Journal of pharmacology and experimental therapeutics.

[62]  John T. Williams,et al.  Morphine-Induced μ-Opioid Receptor Desensitization , 2005, Molecular Pharmacology.

[63]  L. Vanderschuren,et al.  Opioids, reward and addiction: An encounter of biology, psychology, and medicine. , 1999, Pharmacological reviews.

[64]  E. Heinzen,et al.  Neuronal nitric oxide modulates morphine antinociceptive tolerance by enhancing constitutive activity of the μ-opioid receptor , 2005 .

[65]  G. Pasternak,et al.  Nitric oxide and opioid tolerance , 1994, Neuropharmacology.

[66]  C. Chen,et al.  Molecular cloning and expression of a rat kappa opioid receptor. , 1993, The Biochemical journal.

[67]  R. D. du Bois,et al.  No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. , 2006, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[68]  D. Selley,et al.  Region‐dependent attenuation of μ opioid receptor‐mediated G‐protein activation in mouse CNS as a function of morphine tolerance , 2007, British journal of pharmacology.

[69]  G. Pasternak,et al.  Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. , 1996, The Journal of pharmacology and experimental therapeutics.

[70]  Brigitte L. Kieffer,et al.  Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene , 1996, Nature.

[71]  M. Puig,et al.  Expression of opioid receptors during peripheral inflammation. , 2004, Current topics in medicinal chemistry.

[72]  H. Mosberg,et al.  Opioid δ-receptor involvement in supraspinal and spinal antinociception in mice , 1987, Brain Research.

[73]  S. Haraguchi,et al.  Determining the Plasma Concentration of Ketamine That Enhances Epidural Bupivacaine-and-Morphine-Induced Analgesia , 2005, Anesthesia and analgesia.

[74]  A. Young,et al.  Tolerance and cross-tolerance to morphine-like stimulus effects of µ opioids in rats , 1997, Psychopharmacology.

[75]  G. M. Pollack,et al.  Pharmacodynamics and tolerance development during multiple intravenous bolus morphine administration in rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[76]  V. Hruby,et al.  Agonist-specific down-regulation of the human delta-opioid receptor. , 2003, European journal of pharmacology.

[77]  R. Hill,et al.  κ‐Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat , 1988, British journal of pharmacology.

[78]  M. Zarrindast,et al.  On the mechanism of tolerance to morphine-induced Straub tail reaction in mice , 2001, Pharmacology Biochemistry and Behavior.

[79]  Mt Smith,et al.  Neuroexcitatory Effects Of Morphine And Hydromorphone: Evidence Implicating The 3‐Glucuronide Metabolites , 2000, Clinical and experimental pharmacology & physiology.

[80]  Lei Yu,et al.  Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.

[81]  H. Mosberg,et al.  Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice. , 1987, Brain research.

[82]  I. Sora,et al.  Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Steven Edward Kern,et al.  Role of morphine's metabolites in analgesia: Concepts and controversies , 2006, The AAPS Journal.

[84]  L. Dykstra,et al.  Effects of N-methyl-D-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice. , 2005, The journal of pain : official journal of the American Pain Society.

[85]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[86]  S. Allouche,et al.  Different regulation of human delta-opioid receptors by SNC-80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and endogenous enkephalins. , 2004, The Journal of pharmacology and experimental therapeutics.

[87]  Mats O. Karlsson,et al.  Interchangeability and Predictive Performance of Empirical Tolerance Models , 1999, Clinical pharmacokinetics.

[88]  P. Dayer,et al.  Impact of environmental and genetic factors on codeine analgesia , 2004, European Journal of Clinical Pharmacology.

[89]  K. Brouwer,et al.  Pharmacokinetic and Pharmacodynamic Implications of P‐glycoprotein Modulation , 2001, Pharmacotherapy.

[90]  M. Caron,et al.  Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[91]  G. Pasternak,et al.  Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[92]  G. Uhl,et al.  Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. , 1997, The Journal of biological chemistry.

[93]  R. Coggeshall,et al.  Opioid receptors on peripheral sensory axons , 1997, Brain Research.

[94]  M. Esser,et al.  Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. , 2001, Journal of psychiatry & neuroscience : JPN.

[95]  D. Simone,et al.  Peripheral and preemptive opioid antinociception in a mouse visceral pain model , 2001, Pain.

[96]  K. Cosman,et al.  Memantine in the treatment of mild-to-moderate Alzheimer’s disease , 2007, Expert opinion on pharmacotherapy.

[97]  V. Yuferov,et al.  Opioid receptor and peptide gene polymorphisms: potential implications for addictions. , 2000, European journal of pharmacology.

[98]  R. Gracely,et al.  Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal capsaicin in normal subjects. , 1998, Anesthesia and analgesia.

[99]  J. Säwe.  High-Dose Morphine and Methadone in Cancer Patients , 1986, Clinical pharmacokinetics.

[100]  D. Filliol,et al.  A Single Nucleotide Polymorphic Mutation in the Human μ-Opioid Receptor Severely Impairs Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[101]  Y. Wong,et al.  Molecular basis of opioid dependence: role of signal regulation by G‐proteins , 2003, Clinical and experimental pharmacology & physiology.

[102]  Peter J. Denning,et al.  Déjà vu all over again , 2015, CACM.

[103]  L B Sheiner,et al.  Pharmacodynamic model of tolerance: application to nicotine. , 1988, The Journal of pharmacology and experimental therapeutics.

[104]  Jason M. White,et al.  Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations , 2006, Pain.

[105]  Jamie Fong,et al.  Regulation of Opioid Receptor Trafficking and Morphine Tolerance by Receptor Oligomerization , 2002, Cell.

[106]  E. Kelly,et al.  μ-Opioid Receptor Desensitization in Mature Rat Neurons: Lack of Interaction between DAMGO and Morphine , 2003, The Journal of Neuroscience.

[107]  R. Coggeshall,et al.  Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin , 1995, Neuroscience Letters.

[108]  S. Lipton,et al.  The chemical biology of clinically tolerated NMDA receptor antagonists , 2006, Journal of neurochemistry.

[109]  R. Gainetdinov,et al.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. , 2000, Nature.

[110]  R. Coggeshall,et al.  Evidence for the interaction of glutamate and NK1 receptors in the periphery , 1998, Brain Research.

[111]  J. Whistler,et al.  Changes in G Protein-coupled Receptor Sorting Protein Affinity Regulate Postendocytic Targeting of G Protein-coupled Receptors* , 2007, Journal of Biological Chemistry.

[112]  F. Vocci,et al.  The Effects of NMDA Receptor Antagonists and Nitric Oxide Synthase Inhibitors on Opioid Tolerance and Withdrawal , 1995, Neuropsychopharmacology.

[113]  J T Williams,et al.  Cellular and synaptic adaptations mediating opioid dependence. , 2001, Physiological reviews.

[114]  W. Sadee,et al.  Single Nucleotide Polymorphisms in the Human μ Opioid Receptor Gene Alter Basal G Protein Coupling and Calmodulin Binding* , 2001, The Journal of Biological Chemistry.

[115]  D. Joo,et al.  Subpopulation of Dorsal Horn Neurons Displays Enhanced N-methyl-d-aspartate Receptor Function after Chronic Morphine Exposure , 2006, Anesthesiology.

[116]  M. Suzuki,et al.  μ-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to μ-opioid receptor agonists: Comparison between etorphine and morphine , 2006, Neuroscience.

[117]  V. Hruby,et al.  Agonist-specific down-regulation of the human δ-opioid receptor , 2003 .

[118]  K. Brouwer,et al.  Increased brain P-glycoprotein in morphine tolerant rats. , 1999, Life sciences.

[119]  R. Edwards,et al.  Cloning of a delta opioid receptor by functional expression. , 1992, Science.

[120]  G. Wittert,et al.  Tissue distribution of opioid receptor gene expression in the rat. , 1996, Biochemical and biophysical research communications.

[121]  G. Pasternak.  Multiple opiate receptors: déjà vu all over again , 2004, Neuropharmacology.